Skip to main content
SpringerLink
Log in

Anti-inflammatory and antidiabetic effects of grape-derived stilbene concentrate in the experimental metabolic syndrome

  • Research article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Aims

This study aimed to investigate the carbohydrate and lipid dynamics, associated inflammation markers and the effectiveness of a grape-derived stilbene concentrate (GDSC) treatment in experimental metabolic syndrome (MetS).

Methods

The study was carried out on 40 male 12-weeks of age Wistar rats. The MetS was induced using the fructose model (feeding with 60%-solid fructose diet for 24 weeks). Rats with induced MetS were treated with polyphenolic GDSC, which was obtained by water-alcohol extraction of Vitis vinifera grapevine (Ressfood LLC, Russia).

Results

The experimentally induced MetS development leads to classic MetS signs, including abdominal obesity, hyperglycemia, high lipid levels and heart damage. The expression of glucose transporter type 4 (GLUT4) and peroxisome proliferator-activated receptor-γ (PPAR-γ) had greater dynamics than biochemical measurements. The development of the associated inflammatory reactions was confirmed by the increased level of Toll-like receptor type 4 (TLR4) and C-reactive protein (CRP) compared to control levels. The use of the GDSC had positive dynamics in carbohydrate and lipid levels, inflammatory marker, also prevented associated inflammation and heart damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973–4.

    Article  CAS  Google Scholar 

  2. Bernadette Boden-Albala Community Level Disadvantage and the Likelihood of First Ischemic Stroke, Epidemiology Research International. Hindawi Publishing Corporation, 2012 Published online https://doi.org/10.1155/2012/481282

  3. Low Wang C., Hess C., Hiatt W. and Goldfine A. Atherosclerotic cardiovasculr disease and heart failure in type 2 diabetes – mechanisms, management, and clinical considerations. Circulation. 2016; 133(24): 2459–2502. 10.1161.

  4. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. Mol Cell Endocrinol. 2014;382(1):740–57. https://doi.org/10.1016/j.mce.2012.08.018.

    Article  CAS  PubMed  Google Scholar 

  5. Pap A, Cuaranta-Monroy I, Peloquin M, Nagy L. Is the mouse a good model of human PPARγ-related metabolic diseases? Int J Mol Sci. 2016;17(8):1236.

    Article  Google Scholar 

  6. Kintscher U, Goebel M. INT-131, a PPAR-γ agonist for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2009;10(4):381–7.

    CAS  PubMed  Google Scholar 

  7. Gobato AO, Vasques AC, Zambon MP, de Azevedo Barros A, Hessel G. Metabolic syndrome and insulin resistance in obese adolescents. Rev Paul Pediatr. 2014;32(1):55–62.

    Article  Google Scholar 

  8. Krikun G, Trezza J, Shaw J, Rahman M, Guller S, Abrahams VM, et al. Lipopolysaccharide appears to activate human endometrial endothelial cells through TLR-4-dependent and TLR-4-independent mechanisms. Am J Reprod Immunol. 2012;68:233–7.

  9. Ren Z, Zhao A, Wang Y, Meng L, Man-Yau SI. Association between dietary inflammatory index, C-reactive protein and metabolic syndrome: a cross-sectional study. Nutrients. 2018;10(7):831.

    Article  Google Scholar 

  10. Lu P, Sodhi CP, Yamaguchi Y, Jia H, Prindle T Jr, Fulton WB, et al. Intestinal epithelial toll-like receptor 4 prevents metabolic syndrome by regulating interactions between microbes and intestinal epithelial cells in mice. Mucosal Immunol. 2018;11(3):727–40. https://doi.org/10.1038/mi.2017.114.

  11. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.

    Article  CAS  Google Scholar 

  12. Cotillard A, Poitou C, Torcivia A, Bouillot JL, Dietrich A, Kloting N, et al. Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab. 2014;99:E1466–70. https://doi.org/10.1210/jc.2014-1074.

  13. Olson AL. Regulation of GLUT4 and insulin-dependent glucose flux. ISRN Mol Biol. 2012;2012:856987. https://doi.org/10.5402/2012/856987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ferreira DF, Fiamoncini J, Prist IH, Ariga SK, de Souza HP, de Lima TM. Novel role of TLR4 in NAFLD development: modulation of metabolic enzymes expression. Biochim Biophys Acta. 2015;1851(10):1353–9. https://doi.org/10.1016/j.bbalip.2015.07.002.

    Article  CAS  PubMed  Google Scholar 

  15. Shi Y, Jia M, Xu L, Fang Z, et al. miR-96 and autophagy are involved in the beneficial effect of grape seed proanthocyanidins against high-fat-diet-induced dyslipidemia in mice. Phytother Res. 2019;8. https://doi.org/10.1002/ptr.6318.

  16. Sanna RS, Muthangi S, Devi SA. Grape seed proanthocyanidin extract and insulin prevents cognitive decline in type 1 diabetic rat by impacting Bcl-2 and Bax in the prefrontal cortex. Metab Brain Dis. 2019;34(1):103–17. https://doi.org/10.1007/s11011-018-0320-5.Epub2018.

    Article  CAS  PubMed  Google Scholar 

  17. Pascual-Serrano A, Bladé C, Suárez M, Arola-Arnal A. Proanthocyanidins improve white adipose tissue expansion during diet-induced obesity development in rats. Int J Mol Sci. 2018:E2632. https://doi.org/10.3390/ijms19092632.

  18. Samodien E., Pheiffer C., Erasmus M., Mabasa L, Louw J, Johnson R. Diet-induced DNA methylation within the hypothalamic arcuate nucleus and dysregulated leptin and insulin signaling in the pathophysiology of obesity Food Science and Nutrition. – 2019. 7(10). – 2019. – P.3131–3145. https://doi.org/10.1002/fsn3.1169

  19. Salehi B, Mishra A, Nigam M et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6(3):91. Published 2018 Sep 9. https://doi.org/10.3390/biomedicines6030091

  20. Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66. https://doi.org/10.18388/abp.2018_2749.

  21. Rahimifarda M, Shermineh F, Moeini-Nodeh S, et al. Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 2017;36:11–9.

    Article  Google Scholar 

  22. Hajiaghaalipour F, Khalilpourfarshbafi M, Arya A. Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus. Int J Biol Sci. 2015;11(5):508–524. Published 2015 Mar 19. https://doi.org/10.7150/ijbs.11241

  23. Asgary S, Karimi R, Momtaz S, Naseri R, Farzaei MH. Effect of resveratrol on metabolic syndrome components: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2019;20:173–86. https://doi.org/10.1007/s11154-019-09494-z.

    Article  CAS  PubMed  Google Scholar 

  24. Park JH, Kho MC, Kim HY, Ahn YM, Lee YJ, Kang DG, Lee HS. Blackcurrant suppresses metabolic syndrome induced by high-fructose diet in rats. Evid Based Complement Alternat Med. 2015; Published online 2015 Oct 4. https://doi.org/10.1155/2015/385976, 1, 11.

  25. Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC. Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats. PLoS One. 2017;12(7):e0180712. https://doi.org/10.1371/journal.pone.0180712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, 2017.

  27. Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366:1059–62.

    Article  Google Scholar 

  28. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006 May;23(5):469–80.

    Article  CAS  Google Scholar 

  29. Purcell SH, Aerni-Flessner LB, Willcockson AR, Diggs-Andrews KA, Fisher SJ, Moley KH. Improved insulin sensitivity by GLUT12 overexpression in mice. Diabetes. 2011 May;60(5):1478–82.

    Article  CAS  Google Scholar 

  30. Zhou QL, Park JG, Jiang ZY, Holik JJ, Mitra P, Semiz S, et al. Analysis of insulin signalling by RNAi-based gene silencing. Biochem Soc Trans. 2004 Nov;32(Pt 5):817–21.

  31. Kubyshkin A, Ogai Y, Fomochkina I, Chernousova I, et al. Polyphenols of red grape wines and alcohol-free food concentrates in rehabilitation technologies. Polyphenols. 2018:99–120. https://doi.org/10.5772/intechopen.76655.

  32. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ Future Cardiol. 2017;3:279–96. https://doi.org/10.2217/fca-2017-0019.Epub2017.

    Article  Google Scholar 

  33. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557–66. https://doi.org/10.1038/nm.3159.Epub 2013.

  34. Suhett LG, Hermsdorff HHM, Rocha NP, Silva MA, Filgueiras MDS, Milagres LC, et al. Increased C-reactive protein in Brazilian children: association with Cardiometabolic risk and metabolic syndrome components (PASE study). Cardiol Res Pract. 2019;3904568:1–10. https://doi.org/10.1155/2019/3904568.

  35. Reddya P, Lent-Schocheta D, Ramakrishnana N, McLaughlina M, Jialalab I. Metabolic syndrome is an inflammatory disorder: a conspiracy between adipose tissue and phagocytes. Clin Chim Acta. 2019;496:35–44. https://doi.org/10.1016/j.cca.2019.06.019.

    Article  CAS  Google Scholar 

  36. Kim MH, et al. The association between subclinical inflammation and abnormal glucose and lipid metabolisms in normal-weight Korean individuals. Nutr Metab Cardiovasc Dis. 28(11):1106–13.

  37. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92(6):2272–9.

    Article  CAS  Google Scholar 

  38. Petrenko VI, Kubyshkin AV, Fomochkina II, Kucherenko AS, Aliev LL, Sorokina LE, et al. Study of the pathogenetic mechanisms of the pleiotropic action of angiotensin II type 1 receptor blockers in metabolic syndrome. NAMJ. 2019;13(2):18–23.

  39. Li Y, Wende AR, Nunthakungwan O, Huang Y, Hu E, Jin H, et al. Cytosolic, but not mitochondrial, oxidative stress is a likely contributor to cardiac hypertrophy resulting form cardiac specific GLUT4 deletion in mice. FEBS J. 2012;279:599–611.

Download references

Funding

This work was partially supported by the V.I. Vernadsky Crimean Federal University Development Program for 2015–2024.

Author information

Authors and Affiliations

  1. Department of General and Clinical Pathophysiology of Medical Academy named after S.I. Georgievsky (structural unit), V. I. Vernadsky Crimean Federal University, Simferopol, Crimea, Russian Federation, 5/7 Lenin Boulevard, 295051, Russia

    Anatoly Kubyshkin, Alina Shevandova, Vitalina Petrenko, Irina Fomochkina, Leya Sorokina, Alexander Kucherenko, Leonid Aliev, Natalia Kornienko & Ivan Fomochkin

  2. The Central Research Laboratory of the Medical Academy named after S. I. Georgievsky, V. I. Vernadsky Crimean Federal University, Simferopol, Russia

    Andrey Gordienko, Natalia Khimich, Evgenia Zyablitskaya & Tatiana Makalish

Authors
  1. Anatoly Kubyshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alina Shevandova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vitalina Petrenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irina Fomochkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leya Sorokina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander Kucherenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrey Gordienko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Natalia Khimich
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Evgenia Zyablitskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tatiana Makalish
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Leonid Aliev
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Natalia Kornienko
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ivan Fomochkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vitalina Petrenko.

Ethics declarations

Conflict of interest

The authors declare no conflict of interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kubyshkin, A., Shevandova, A., Petrenko, V. et al. Anti-inflammatory and antidiabetic effects of grape-derived stilbene concentrate in the experimental metabolic syndrome. J Diabetes Metab Disord 19, 1205–1214 (2020). https://doi.org/10.1007/s40200-020-00626-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-020-00626-w

Keywords

Search

Navigation